Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Jurnista Hydromorphone hydrochloride Pain, Chronic (moderate to severe) Do not list Complete
Juxtapid Lomitapide Hypercholesterolemia, homozygous familial Do not list Complete
Kadcyla Trastuzumab Emtansine Early Breast Cancer (EBC) Reimburse Complete
Kadcyla Trastuzumab emtansine Advanced or Metastatic Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Kalydeco Ivacaftor Cystic Fibrosis, CFTR gating mutations List with criteria/condition Complete
Kalydeco Ivacaftor Cystic fibrosis, R117H CFTR gating mutation List with criteria/condition Complete
Kalydeco Ivacaftor Cystic fibrosis, G551D mutation List with criteria/condition Complete
Kanuma sebelipase alfa Lysosomal acid lipase deficiency Reimburse with clinical criteria and/or conditions Complete
Kazano Alogliptin plus metformin Diabetes mellitus, type 2 Do not list Complete
Kerendia finerenone Chronic kidney disease Reimburse with clinical criteria and/or conditions Complete